Investments
121Portfolio Exits
43About Boxer Capital
Boxer Capital is a vehicle for Tavistock Life Science's investment in a portfolio of public companies and private equity crossover opportunities. Boxer Capital leverages its internal expertise in evaluating pre-clinical and clinical data to generate outsized returns for company founders and employees as well for its investor the Tavistock Group. Boxer Capital has a focus on biotechnology drug development companies across multiple therapeutic indications.

Want to inform investors similar to Boxer Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Boxer Capital News
Feb 23, 2023
Abivax SA raises €130m to advance obefazimod to Phase III French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow. Existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others participated in the overtsubscribed reserved capital increase through the issuance of 20,000,000 newly-issued ordinary shares with a nominal value of €0.01 per share, representing 89.6% of its current share capital, at a subscription price of €6.50 per share. Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax said: “Based on our consistent Phase IIa and Phase IIb data, we expect that the Phase III studies will support the short- and long-term efficacy and safety profile of obefazimod.” Alongside the launch and continuation of the clinical programs of obefazimod (ABX464), the company extended its cash runway until the end of the second quarter of 2024. For ulcerative colitis, Abiivax’ pivotal Phase III program started enrollment in October 2022. The program will combine two induction trials and one single maintenance trial, involving a total of 1,200 patients and over 600 clinical study centres, mainly in North America, Europe, Latin America and Asia Pacific. Abivax will invest 80% of the proceeds into the Phase III trial of obefazimod, R&D on the compound’s mechanism of action, nonclinical work, chemical and pharmaceutical development work, regulatory and pharmacovigilance activities for obefazimod. Around 10% will be invested into the remaining clinical activities for obefazimod outside the ulcerative colitis indication such as a Phase IIa maintenance trial in rheumatoid arthritis and various current and future Phase I trials necessary to prepare potential submissions for marketing authorisations for obefazimod. Abivax said that it will require additional financing of €101m to complete its Phase III clinical program for obefazimod in UC.
Boxer Capital Investments
121 Investments
Boxer Capital has made 121 investments. Their latest investment was in Abivax as part of their PIPE - III on February 2, 2023.

Boxer Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
2/22/2023 | PIPE - III | Abivax | $137.85M | Yes | 1 | |
11/2/2022 | Series A | Lusaris Therapeutics | $60M | Yes | Boxer Capital, Deep Track Capital, RA Capital Management, Undisclosed Investors, and Venrock Healthcare Capital Partners | 12 |
11/2/2022 | Series A - II | Alterome Therapeutics | $35M | No | 5 | |
9/7/2022 | PIPE | |||||
3/31/2022 | Series B |
Date | 2/22/2023 | 11/2/2022 | 11/2/2022 | 9/7/2022 | 3/31/2022 |
---|---|---|---|---|---|
Round | PIPE - III | Series A | Series A - II | PIPE | Series B |
Company | Abivax | Lusaris Therapeutics | Alterome Therapeutics | ||
Amount | $137.85M | $60M | $35M | ||
New? | Yes | Yes | No | ||
Co-Investors | Boxer Capital, Deep Track Capital, RA Capital Management, Undisclosed Investors, and Venrock Healthcare Capital Partners | ||||
Sources | 1 | 12 | 5 |
Boxer Capital Portfolio Exits
43 Portfolio Exits
Boxer Capital has 43 portfolio exits. Their latest portfolio exit was Enliven Therapeutics on February 23, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/23/2023 | Reverse Merger | 4 | |||
9/15/2022 | IPO | Public | 18 | ||
8/10/2022 | Acq - Pending | 2 | |||
Date | 2/23/2023 | 9/15/2022 | 8/10/2022 | ||
---|---|---|---|---|---|
Exit | Reverse Merger | IPO | Acq - Pending | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 18 | 2 |
Boxer Capital Team
7 Team Members
Boxer Capital has 7 team members, including current Founder, Chief Executive Officer, Aaron Davis.
Name | Work History | Title | Status |
---|---|---|---|
Aaron Davis | Founder, Chief Executive Officer | Current | |
Name | Aaron Davis | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder, Chief Executive Officer | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.